BACKGROUND: Left ventricular hypertrophy involves growth of cardiomyocytes, as well as remodeling of extracellular matrix proteins (ECMPs). Several metabolic abnormalities may be triggered secondary to hyperglycemia in diabetes. The effects of combined supravalvular aortic banding and diabetes mellitus on the rat heart were investigated in order to detect possible synergistic effects of these two conditions. Moreover, this study focused on the impact of beta-adrenoceptor blockade with carvedilol (C) on the expression of ECMPs. METHODS: Sixty male Wistar rats were allocated to six groups: control (CON), CON+C, streptozotocin (65 mg/kg iv)-induced diabetes (D), D+C, aortic stenosis (AS)+D and AS+D+C. Follow-up was 6 weeks. RESULTS: Relative left ventricular weight was elevated and body weight was decreased in D, AS+D and AS+D+C rats (P<.05 vs. CON). Diabetes elevated cardiomyocyte widths, perivascular/interstitial fibrosis (P<.01 each), as well as ECMPs: collagen I/fibronectin/laminin were 3.4-fold/4.1-fold/1.5-fold elevated in D rats and further increased (4.6-fold/5.9-fold/1.9-fold) in AS+D rats (P<.01 vs. CON). Heart rate and blood pressure decreased in D and AS+D rats (P<.05 vs. CON). Carvedilol application attenuated the overexpression of ECMPs. CONCLUSIONS: Beta-adrenoceptor blockade results in regression of the hypertrophic phenotype and in decrease of ECMP in rats with experimental diabetes and in animals with combined chronic pressure overload and hyperglycemia. These results represent a new mechanism of carvedilol that may contribute to the observed beneficial effects in heart failure.
BACKGROUND:Left ventricular hypertrophy involves growth of cardiomyocytes, as well as remodeling of extracellular matrix proteins (ECMPs). Several metabolic abnormalities may be triggered secondary to hyperglycemia in diabetes. The effects of combined supravalvular aortic banding and diabetes mellitus on the rat heart were investigated in order to detect possible synergistic effects of these two conditions. Moreover, this study focused on the impact of beta-adrenoceptor blockade with carvedilol (C) on the expression of ECMPs. METHODS: Sixty male Wistar rats were allocated to six groups: control (CON), CON+C, streptozotocin (65 mg/kg iv)-induced diabetes (D), D+C, aortic stenosis (AS)+D and AS+D+C. Follow-up was 6 weeks. RESULTS: Relative left ventricular weight was elevated and body weight was decreased in D, AS+D and AS+D+C rats (P<.05 vs. CON). Diabetes elevated cardiomyocyte widths, perivascular/interstitial fibrosis (P<.01 each), as well as ECMPs: collagen I/fibronectin/laminin were 3.4-fold/4.1-fold/1.5-fold elevated in D rats and further increased (4.6-fold/5.9-fold/1.9-fold) in AS+D rats (P<.01 vs. CON). Heart rate and blood pressure decreased in D and AS+D rats (P<.05 vs. CON). Carvedilol application attenuated the overexpression of ECMPs. CONCLUSIONS: Beta-adrenoceptor blockade results in regression of the hypertrophic phenotype and in decrease of ECMP in rats with experimental diabetes and in animals with combined chronic pressure overload and hyperglycemia. These results represent a new mechanism of carvedilol that may contribute to the observed beneficial effects in heart failure.
Authors: Xiao Ma; Markus Wehland; Herbert Schulz; Katrin Saar; Norbert Hübner; Manfred Infanger; Johann Bauer; Daniela Grimm Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240
Authors: Jessica Pietsch; Stefan Riwaldt; Johann Bauer; Albert Sickmann; Gerhard Weber; Jirka Grosse; Manfred Infanger; Christoph Eilles; Daniela Grimm Journal: Int J Mol Sci Date: 2013-01-09 Impact factor: 5.923